January 2025

ZURICH and NESS ZIONA, Israel, Jan. 8, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kad

ZURICH and NESS ZIONA, Israel, Jan. 8, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kad

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: